1. Home
  2. ALIT vs FULC Comparison

ALIT vs FULC Comparison

Compare ALIT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alight Inc.

ALIT

Alight Inc.

HOLD

Current Price

$0.75

Market Cap

496.4M

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.66

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALIT
FULC
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
496.4M
467.8M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
ALIT
FULC
Price
$0.75
$3.66
Analyst Decision
Buy
Buy
Analyst Count
6
8
Target Price
$3.75
$16.38
AVG Volume (30 Days)
25.6M
2.4M
Earning Date
05-05-2026
04-27-2026
Dividend Yield
21.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,262,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$2.83
52 Week High
$6.03
$15.74

Technical Indicators

Market Signals
Indicator
ALIT
FULC
Relative Strength Index (RSI) 43.37 25.82
Support Level $0.67 N/A
Resistance Level $1.01 $8.18
Average True Range (ATR) 0.09 0.35
MACD -0.02 -0.34
Stochastic Oscillator 6.43 18.40

Price Performance

Historical Comparison
ALIT
FULC

About ALIT Alight Inc.

Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: